Immune Design Corp (NASDAQ:IMDZ) CEO Carlos V. Paya sold 7,970 shares of Immune Design stock in a transaction on Friday, January 5th. The shares were sold at an average price of $4.17, for a total value of $33,234.90. Following the completion of the sale, the chief executive officer now owns 114,560 shares in the company, valued at approximately $477,715.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Immune Design Corp (NASDAQ:IMDZ) opened at $3.65 on Thursday. The stock has a market capitalization of $175.41, a price-to-earnings ratio of -1.71 and a beta of 2.36. Immune Design Corp has a 1-year low of $3.50 and a 1-year high of $13.05.

Immune Design (NASDAQ:IMDZ) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.62 million. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. analysts expect that Immune Design Corp will post -1.89 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the stock. State of Wisconsin Investment Board purchased a new stake in Immune Design during the 2nd quarter worth about $117,000. Alliancebernstein L.P. purchased a new stake in Immune Design during the 2nd quarter worth about $118,000. Virtu KCG Holdings LLC purchased a new stake in Immune Design during the 2nd quarter worth about $153,000. Dimensional Fund Advisors LP increased its holdings in Immune Design by 9.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 1,600 shares during the period. Finally, Rhumbline Advisers increased its holdings in Immune Design by 53.9% during the 2nd quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 6,896 shares during the period. Hedge funds and other institutional investors own 29.34% of the company’s stock.

A number of research firms have commented on IMDZ. Zacks Investment Research downgraded Immune Design from a “buy” rating to a “hold” rating in a research report on Monday. ValuEngine downgraded Immune Design from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Royal Bank of Canada began coverage on Immune Design in a report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price objective on the stock. Wells Fargo & Co downgraded Immune Design from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. Finally, Cowen reiterated a “buy” rating on shares of Immune Design in a report on Monday, December 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.06.

TRADEMARK VIOLATION WARNING: “Immune Design Corp (IMDZ) CEO Sells $33,234.90 in Stock” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2018/01/11/immune-design-corp-imdz-ceo-sells-33234-90-in-stock.html.

About Immune Design

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design (NASDAQ:IMDZ)

Receive News & Stock Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related stocks with our FREE daily email newsletter.